Validation of Turkish Versions Child- and Parent-Rated Scales of Food Allergy Anxiety
Assessment of the Validity and Reliability of the Turkish Adaptation of the Child- and Parent-Rated Scales of Food Allergy Anxiety (SOFAA)
1 other identifier
observational
105
1 country
1
Brief Summary
This study aims to evaluate the psychometric properties of the Turkish adaptation of the Scale of Food Allergy Anxiety (SOFAA), including both the child-report and parent-report versions. The SOFAA is a validated tool originally developed to assess the specific anxiety related to food allergies. The Turkish versions of the scales will undergo a comprehensive validation process, including assessments of internal consistency, test-retest reliability, and construct validity. Participants will include children diagnosed with IgE-mediated food allergies and their primary caregivers. The study will investigate whether the translated scales maintain the original structure and effectively measure food allergy-related anxiety in the Turkish pediatric population. The findings are expected to contribute to clinical assessment practices and research on food allergy-related psychosocial impacts in Turkeyy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 13, 2023
CompletedFirst Submitted
Initial submission to the registry
June 4, 2025
CompletedFirst Posted
Study publicly available on registry
June 13, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 30, 2027
June 24, 2025
June 1, 2025
3.6 years
June 4, 2025
June 18, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Internal Consistency of the Turkish Version of the SOFAA-C and SOFAA-P
Internal consistency of the Turkish child- and parent-reported versions of the Scale of Food Allergy Anxiety (SOFAA) will be evaluated using Cronbach's alpha coefficient. A value of ≥ 0.70 will be considered acceptable.
Within 1 week of initial administration
Construct Validity of the Turkish Version of SOFAA
Construct validity of the Turkish version of the SOFAA will be assessed using exploratory and/or confirmatory factor analysis based on responses from children and parents. Factor structure will be compared with the original version.
Within 1 week of initial administration
Test-Retest Reliability of the Turkish Version of SOFAA
A subsample of participants will complete the SOFAA again after a 10-14 day interval. Test-retest reliability will be evaluated using intraclass correlation coefficient (ICC).
Approximately 10-14 days after baseline assessment
Study Arms (2)
Children with Food Allergy
Children aged 8 to 18 years diagnosed with IgE-mediated food allergy, recruited from pediatric allergy clinics. Participants complete the Turkish-translated child version of the Scale of Food Allergy Anxiety (SOFAA-C).
Parents of Children with Food Allergy
Parents or primary caregivers of the participating children complete the parent version of the Turkish-translated Scale of Food Allergy Anxiety (SOFAA-P)
Interventions
Participants will complete the Turkish-translated versions of the Scale of Food Allergy Anxiety (SOFAA). Children will complete the SOFAA-C; their parents will complete the SOFAA-P. The study aims to evaluate the reliability and validity of the translated scales through internal consistency, factor analysis, and test-retest reliability methods.
Eligibility Criteria
Children aged 8-18 with food allergy and their parents, recruited from pediatric allergy outpatient clinics in Turkey.
You may qualify if:
- Diagnosed with IgE-mediated food allergy
- At least one parent/caregiver willing to participate
- Fluent in Turkish
You may not qualify if:
- Major neurodevelopmental or psychiatric disorders that impair ability to complete scales
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Istanbul, Turkey (Türkiye)
Related Publications (2)
Protudjer JLP. Scales of Food Allergy Anxiety (SOFAA): A Novel Tool to Assess Anxiety Among Children with Food Allergy and Their Caregivers. J Allergy Clin Immunol Pract. 2022 Jan;10(1):170-171. doi: 10.1016/j.jaip.2021.10.036. No abstract available.
PMID: 35000731BACKGROUNDDahlsgaard KK, Wilkey LK, Stites SD, Lewis MO, Spergel JM. Development of the Child- and Parent-Rated Scales of Food Allergy Anxiety (SOFAA). J Allergy Clin Immunol Pract. 2022 Jan;10(1):161-169.e6. doi: 10.1016/j.jaip.2021.06.039. Epub 2021 Jul 12.
PMID: 34265450BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Doctor, Clinical Fellow in Pediatric Allergy and Immunology
Study Record Dates
First Submitted
June 4, 2025
First Posted
June 13, 2025
Study Start
July 13, 2023
Primary Completion (Estimated)
January 30, 2027
Study Completion (Estimated)
January 30, 2027
Last Updated
June 24, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- CSR
- Time Frame
- Aggregate data will be available beginning 6 months after study completion and for a period of up to 5 years thereafter.
- Access Criteria
- Researchers with a methodologically sound proposal may request access to the aggregated study data. Requests should be submitted to the principal investigator and will require appropriate ethical approval and a signed data-sharing agreement.
Only aggregate results (e.g., internal consistency coefficients, summary statistics) will be shared. Individual participant data (IPD), even in de-identified form, will not be made publicly available. Access to data may be considered upon reasonable request and with appropriate ethical approvals.